何玉先，1966年生，籍贯安徽萧县，病毒学家，病原生物学研究所研究员，博士生导师。1990-1993年在中国预防医学科学院劳动卫生与职业病学专业攻读硕士学位，从事矽肺致病机制及治疗研究。2005-2007年在德国乌尔姆大学医学病毒学专业攻读博士学位，从事艾滋病分子病毒学研究。1997-2008年曾任职美国洛克菲勒大学访问学者、纽约大学博士后研究员和纽约血液中心助理研究员，主要研究艾滋病及新发重大传染病研究。2008年4月回国任职病原生物学研究所研究员。

艾滋病病毒感染机制、抗病毒药物及基因治疗策略，新型冠状病毒膜融合的分子机制及强效抑制剂研发

1. Xue J#*, Chong H#, Zhu Y#, Zhang J, Tong L, Lu J, Chen T, Cong Z, Wei Q, He Y*. 2022. Efficient treatment and pre-exposure prophylaxis in rhesus macaques by an HIV fusion-inhibitory lipopeptide. Cell. 185(1): 131-44. (IF=66.850)

2. Zhu Y#, Dong X#, Liu N, Wu T, Chong H, Lei X, Ren L, Wang J*, He Y*. 2022. SARS-CoV-2 fusion-inhibitory lipopeptides maintain high potency against divergent variants of concern including Omicron. Emerg Microbes Infect. 11(1):1819-27. (IF=19.568)

3. Chen Y, Jin H*, Tang X, Li L, Geng X, Zhu Y, Chong H, He Y*. 2022. Cell membrane-anchored anti-HIV single-chain antibodies and bifunctional inhibitors targeting the gp41 fusion protein: new strategies for HIV gene therapy. Emerg Microbes Infect. 11(1):30-49. (IF=19.568)

4. Zhu Y#, Yu D#, Hu Y#, Wu T, Chong H, He Y*. 2021. SARS-CoV-2 derived fusion inhibitor lipopeptides exhibit highly potent and broad-spectrum activity against divergent human coronaviruses. Signal Transduct Target Ther. 6(1):294. (IF=19.568)

5. Yu D#, Zhu Y#, Jiao T#, Wu T#, Xiao X, Qin B, Hu Y, Chong H, Lei X, Ren L, Cui S*, Wang J*, He Y*. 2021. Structure-based design and characterization of novel fusion-inhibitory lipopeptides against SARS-CoV-2 and emerging variants. Emerg Microbes Infect. 10(1):1227-40. (IF=7.163)

6. Yu D#, Zhu Y#, Yan H#, Wu T, Chong H, He Y*. 2021. Pan-coronavirus fusion inhibitors possess potent inhibitory activity against HIV-1, HIV-2, and simian immunodeficiency virus. Emerg Microbes Infect. 10(1):810-21. (IF=7.163)

7. Jin H, Tang X, Li L, Chen Y, Zhu Y, Chong H, He Y*. 2021. Generation of HIV-resistant cells with a single-domain antibody: implications for HIV-1 gene therapy. Cell Mol Immunol. 18(3): 660-74. (IF=11.530)

8. Zhu Y#, Yu D#, Han Y#, Yan H, Chong H, Ren L, Wang J*, Li T*, He Y*. 2020. Cross-reactive neutralization of SARS-CoV-2 by serum antibodies from recovered SARS patients and immunized animals. Sci Adv. 6(45): eabc9999. (IF=14.136)

9. Chong H#, Xue J#, Zhu Y#, Cong Z, Chen T, Wei Q, Qin C*, He Y*. 2019. Monotherapy with a low-dose lipopeptide HIV fusion inhibitor maintains long-term viral suppression in rhesus macaques. PLoS Pathog. 15(2):e1007552. (IF=6.463)

10. He Y*, Cheng J, Lu H, Li J, Hu J, Qi Z, Liu Z, Jiang S, Dai Q*. 2008. Potent HIV fusion inhibitors against Enfuvirtide-resistant HIV-1 strains. Proc Natl Acad Sci USA. 105(42):16332-7. (IF=9.380)